Core Viewpoint - The article discusses the recent investment by Betaini, a publicly listed company, in the Jin Yu Fund, highlighting the strategic move to seek new growth opportunities in the healthcare sector amidst declining market performance [5][9][10]. Investment Details - Betaini has committed 50 million yuan to the Jin Yu Fund, which has a total subscription amount of 1 billion yuan and a partnership duration of 10 years [7][9]. - The Jin Yu Fund is managed by Jin Yu Mao Wu, a venture capital firm based in Jiangsu, focusing on strategic emerging industries such as new materials, renewable energy, and healthcare [7][9]. - The largest limited partner (LP) in the fund is the Jiangsu Wuxi Biomedical Industry Special Mother Fund, contributing 300 million yuan, accounting for 30% of the fund [7][8]. Company Background - Betaini is known for its skincare brand Winona, which has gained significant market share in the sensitive skin segment, previously exceeding a market capitalization of 120 billion yuan but has now fallen below 20 billion yuan [9][10]. - The company is facing intense competition in the cosmetics market, leading to a 49.01% decline in net profit in the first half of the year [10]. Strategic Rationale - The investment in the Jin Yu Fund is part of Betaini's strategy to deepen collaboration with professional funds and enhance its presence in the health ecosystem, aiming to improve its overall competitiveness and profitability [10][12]. - This is not Betaini's first investment with Jin Yu Mao Wu; the company previously invested 30 million yuan in another fund managed by the same firm, indicating a pattern of strategic partnerships [12]. Industry Context - The trend of companies becoming LPs in venture capital funds is becoming more common, as firms seek to leverage established relationships and trust with previous investors [13]. - The current investment landscape shows a scarcity of willing social capital, making corporate LPs a vital resource in the market [13].